Linked Life Data

18214034

Source:http://linkedlifedata.com/resource/pubmed/id/18214034

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18214034rdf:typepubmed:Citationlld:pubmed
pubmed-article:18214034lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:18214034lifeskim:mentionsumls-concept:C1711254lld:lifeskim
pubmed-article:18214034lifeskim:mentionsumls-concept:C1516196lld:lifeskim
pubmed-article:18214034lifeskim:mentionsumls-concept:C0006141lld:lifeskim
pubmed-article:18214034lifeskim:mentionsumls-concept:C0449259lld:lifeskim
pubmed-article:18214034lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:18214034lifeskim:mentionsumls-concept:C1511024lld:lifeskim
pubmed-article:18214034pubmed:issue6Clld:pubmed
pubmed-article:18214034pubmed:dateCreated2008-1-24lld:pubmed
pubmed-article:18214034pubmed:abstractTextMutations in the BRCA1/2 genes confer a high risk for breast and ovarian cancer, with usually adverse clinical characteristics. The clinical course and response to treatment in mutation carriers have been reported infrequently and are assumed to be worse than in sporadic breast cancer.lld:pubmed
pubmed-article:18214034pubmed:languageenglld:pubmed
pubmed-article:18214034pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18214034pubmed:citationSubsetIMlld:pubmed
pubmed-article:18214034pubmed:statusMEDLINElld:pubmed
pubmed-article:18214034pubmed:issn0250-7005lld:pubmed
pubmed-article:18214034pubmed:authorpubmed-author:KatajaVesaVlld:pubmed
pubmed-article:18214034pubmed:authorpubmed-author:KosmaVeli-Mat...lld:pubmed
pubmed-article:18214034pubmed:authorpubmed-author:HeinonenSeppo...lld:pubmed
pubmed-article:18214034pubmed:authorpubmed-author:MannermaaArto...lld:pubmed
pubmed-article:18214034pubmed:authorpubmed-author:HartikainenJa...lld:pubmed
pubmed-article:18214034pubmed:issnTypePrintlld:pubmed
pubmed-article:18214034pubmed:volume27lld:pubmed
pubmed-article:18214034pubmed:ownerNLMlld:pubmed
pubmed-article:18214034pubmed:authorsCompleteYlld:pubmed
pubmed-article:18214034pubmed:pagination4295-300lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:meshHeadingpubmed-meshheading:18214034...lld:pubmed
pubmed-article:18214034pubmed:articleTitleA BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.lld:pubmed
pubmed-article:18214034pubmed:affiliationInstitute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Finland. jaana.hartikainen@uku.filld:pubmed
pubmed-article:18214034pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18214034pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:675entrezgene:pubmedpubmed-article:18214034lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18214034lld:entrezgene
lhgdn:association:16233lhgdn:found_inpubmed-article:18214034lld:lhgdn